PERIPHERAL T-CELL LYMPHOMA, NOT OTHERWISE SPECIFIED
Clinical trials for PERIPHERAL T-CELL LYMPHOMA, NOT OTHERWISE SPECIFIED explained in plain language.
Never miss a new study
Get alerted when new PERIPHERAL T-CELL LYMPHOMA, NOT OTHERWISE SPECIFIED trials appear
Sign up with your email to follow new studies for PERIPHERAL T-CELL LYMPHOMA, NOT OTHERWISE SPECIFIED, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New hope for rare lymphoma: drug may prevent relapse
Disease control Not yet recruitingThis study tests whether the drug duvelisib can help prevent peripheral T-cell lymphoma from returning after initial treatment. About 25 adults whose cancer has disappeared after first-line therapy will take duvelisib as maintenance. The goal is to see if it extends the time befo…
Matched conditions: PERIPHERAL T-CELL LYMPHOMA, NOT OTHERWISE SPECIFIED
Phase: PHASE2 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated May 26, 2026 04:35 UTC
-
New hope for rare lymphoma: targeted drug plus chemo enters first human tests
Disease control Not yet recruitingThis early-phase trial tests whether adding the targeted drug ruxolitinib to standard chemotherapy (CHOP) is safe and effective for people with untreated nodal T-follicular helper (TFH) cell lymphoma, a rare blood cancer. About 20 adults will take part to find the best dose and w…
Matched conditions: PERIPHERAL T-CELL LYMPHOMA, NOT OTHERWISE SPECIFIED
Phase: PHASE1 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated May 11, 2026 20:50 UTC